COMP <GO>
BFRI vs ALLR // EV/EBITDA & P/E VALUATION
Biofrontera Inc. (NASDAQ) VS. Allarity Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: BFRI 2
— ALLR 1
■ METRIC PARITY
LAST: $0.93 (+5.09%) • MKT CAP: $13.8M
valuation
—
LAST: $0.89 (-6.32%) • MKT CAP: $14.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BFRI VS. ALLR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BFRI | ALLR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -27.20% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -25.30% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 11.70% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | BFRI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.2 | 38.9 | +3.36 | BFRI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $13.8M | $14.2M | -$325.6K | ALLR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BFRI REV | ALLR REV | BFRI GROSS % | ALLR GROSS % | BFRI FCF | ALLR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $41.7M | $0 | — | — | -$13.4M | -$14.8M |
| FY 2024 | $37.3M | $0 | — | — | -$10.3M | -$17.6M |
| FY 2023 | $34.1M | $0 | — | — | -$24.9M | -$12.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BFRI // BETA —
ALLR // BETA —